Simple Summary Recently observed improvement in the treatment of pancreatic ductal
adenocarcinoma (PDAC) has resulted mainly from improved perioperative care and more …

Pancreatic cancer has traditionally been associated with a dismal prognosis, even in early
stages of the disease. In recent years, the introduction of newer generation chemotherapy …

The management of pancreatic ductal adenocarcinoma (PDAC) has evolved over the last
two decades. Surgical resection remain the only potential cure for this cancer. Therefore …

Simple Summary Pancreatic cancer usually presents late when it has spread to distant sites.
In a small proportion of patients, the cancer can be removed by surgery. Surgery is usually …

Background Several new treatment options have become available for pancreatic ductal
adenocarcinoma (PDAC), but the support for their use for resectable, borderline resectable …

Approximately 20% of pancreatic ductal adenocarcinoma (PDAC) patients have (borderline)
resectable pancreatic cancer [(B) RPC] at diagnosis. Upfront resection with adjuvant …

Patients with localized pancreatic ductal adenocarcinoma (PDAC) are best treated with
surgical resection of the primary tumour and systemic chemotherapy, which provides …

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with limited
effective therapeutic options and exceedingly high mortality rates. Currently, cure can only …

Abstract Background Only 15–20% of patients with pancreatic ductal adenocarcinoma
(PDAC) have a resectable tumor at the time of diagnosis. Effective multimodal treatment …

Patients with pancreatic ductal adenocarcinoma (PDAC) usually have a dismal prognosis,
and even after curative resection most patients will have disease relapse and ultimately die …